A small trial has found that radiotherapy led to a “dramatic” slowing of prostate cancer progression, increasing time with normal testosterone. “Metastasis-directed therapy combined with hormone therapy as part of an intermittent regimen improves PFS and thus time off from hormone therapy,” said Chad Tang, MD, of the University of Texas MD Anderson Cancer Center in Houston.